Ken Keller is currently President, Daiichi Sankyo Administrative and Commercial for Daiichi Sankyo, Inc. and President and CEO Luitpold Pharmaceuticals, Inc. Ken has more than 25 years of experience in the pharmaceutical industry in sales and marketing leadership, general management and joint venture leadership, as well as chief operating officer experience in several therapeutic areas including oncology, rheumatology, dermatology and primary care. Prior to joining the Daiichi Sankyo Group, Mr. Keller was the Chief Operating Officer at Spectrum Pharmaceuticals, where he had global responsibility for leading commercial operations, medical and clinical development, regulatory, quality, safety and pharmaceutical operations. Under his leadership, Spectrum's portfolio grew from two to four marketed products, and has effectively advanced a number of product candidates through pivotal studies. Prior to joining Spectrum, Mr. Keller spent 21 years at Amgen. His most recent role was Vice President and General Manager, Bone Health Business Unit. Previous to this role, he was responsible for the Inflammation Business Unit which contributed more than $3 billion in revenue. During his career at Amgen, Mr. Keller was the marketing lead or the general manager for four of the world's top selling biologic medicines Neupogen®, Neulasta®, Aranesp® and Enbrel®. He also has significant international experience as managing director for Amgen's United Kingdom and Ireland Affiliate. Mr. Keller holds a Bachelors of Science degree in Business from Saint John's University and a Masters in Business Administration from Loyola Marymount Univ

 Ken Keller is currently President, Daiichi Sankyo Administrative and Commercial for Daiichi Sankyo, Inc. and President and CEO Luitpold Pharmaceuticals, Inc. Ken has more than 25 years of experience in the pharmaceutical industry in sales and marketing leadership, general management and joint venture leadership, as well as chief operating officer experience in several therapeutic areas including oncology, rheumatology, dermatology and primary care. Prior to joining the Daiichi Sankyo Group, Mr. Keller was the Chief Operating Officer at Spectrum Pharmaceuticals, where he had global responsibility for leading commercial operations, medical and clinical development, regulatory, quality, safety and pharmaceutical operations. Under his leadership, Spectrum's portfolio grew from two to four marketed products, and has effectively advanced a number of product candidates through pivotal studies. Prior to joining Spectrum, Mr. Keller spent 21 years at Amgen. His most recent role was Vice President and General Manager, Bone Health Business Unit. Previous to this role, he was responsible for the Inflammation Business Unit which contributed more than $3 billion in revenue. During his career at Amgen, Mr. Keller was the marketing lead or the general manager for four of the world's top selling biologic medicines Neupogen®, Neulasta®, Aranesp® and Enbrel®. He also has significant international experience as managing director for Amgen's United Kingdom and Ireland Affiliate. Mr. Keller holds a Bachelors of Science degree in Business from Saint John's University and a Masters in Business Administration from Loyola Marymount Univ